» Articles » PMID: 39697346

Heterogeneous Immune Landscapes and Macrophage Dynamics in Primary and Lung Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Overview
Journal Front Immunol
Date 2024 Dec 19
PMID 39697346
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Recurrent or metastatic adenoid cystic carcinoma (ACC) of the head and neck is rare and highly aggressive. Due to the ineffectiveness of immune checkpoint therapies, this study aims to investigate the tumor immune microenvironment of primary tumor tissues and lung metastatic tissues and to comprehend the challenges of immunotherapy.

Methods: We analyzed RNA sequencing data and constructed immune landscapes from 25 primary tumors and 34 lung metastases. The data were then validated by immunohistochemistry and single-cell sequencing analysis.

Results: Compared to adjacent normal tissues, both primary and lung metastatic ACC showed low immune infiltration. Lung metastases had higher immune infiltration levels and antigen presentation scores but also higher T cell exclusion and dysfunction scores. Single-cell sequencing data and immunohistochemistry revealed abundant immunosuppressive tumor-associated macrophages in lung metastases. Patients with high M2 macrophage infiltration had shorter lung metastasis-free survival.

Discussion: Primary and lung metastatic ACC exhibit heterogeneous tumor immune microenvironments. Higher immune cell infiltration in lung metastases is countered by the presence of suppressive tumor-associated macrophages, which may limit effective anti-tumor responses.

References
1.
Deng Z, Xiao M, Du D, Luo N, Liu D, Liu T . DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer. Onco Targets Ther. 2021; 14:2003-2017. PMC: 7987320. DOI: 10.2147/OTT.S294332. View

2.
Hanna G, ONeill A, Cutler J, Flynn M, Vijaykumar T, Clark J . A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021; 119:105366. DOI: 10.1016/j.oraloncology.2021.105366. View

3.
Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

4.
Redondo-Garcia S, Barritt C, Papagregoriou C, Yeboah M, Frendeus B, Cragg M . Human leukocyte immunoglobulin-like receptors in health and disease. Front Immunol. 2023; 14:1282874. PMC: 10679719. DOI: 10.3389/fimmu.2023.1282874. View

5.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View